" /> Trametinib Dimethyl Sulfoxide - CISMeF





Preferred Label : Trametinib Dimethyl Sulfoxide;

NCIt definition : A dimethyl sulfoxide (DMSO) solvated form of trametinib, an orally bioavailable inhibitor of mitogen-activated protein kinase kinase (MAP2K; MAPK/ERK kinase; MEK) 1 and 2, with potential antineoplastic activity. Upon oral administration, trametinib specifically binds to and inhibits MEK 1 and 2, resulting in an inhibition of growth factor-mediated cell signaling and cellular proliferation in various cancers. MEK 1 and 2, dual specificity serine/threonine and tyrosine kinases often upregulated in various cancer cell types, play a key role in the activation of the RAS/RAF/MEK/ERK signaling pathway that regulates cell growth.;

UNII : BSB9VJ5TUT;

InChIKey : OQUFJVRYDFIQBW-UHFFFAOYSA-N;

CAS number : 1187431-43-1; a href https://gsrs.ncats.nih.gov/ginas/app/beta/browse-substance?search 1187431-43-1 alt lien vers site G-SRS target _blank img src /img/logos/logo_g-srs.png alt Logo G-SRS /a ;

Drug name : Mekinist; Meqsel;

NCI Metathesaurus CUI : CL553915;

Details


Keyword's position in hierarchy(ies) : arborescence

You can consult :


Nous contacter.
12/05/2024


[Home] [Top]

© Rouen University Hospital. Any partial or total use of this material must mention the source.